Entrepreneurship for Cardiovascular Health Opportunities (ECHO) is a 12-month national training program supporting cardiovascular research commercialization through education, mentorship, networking, and funding. Led by a diverse team of experts, ECHO fosters...
New study using stem cells highlights myosin inhibitors as targeted treatment for pediatric hypertrophic cardiomyopathy
Cardiomyopathy is a leading cause of heart failure in children, and there are currently no effective treatments. Could emerging therapies that successfully target the root cause of the condition in adults also work well in children? That was the question Dr....PRIMaCY Risk Calculator Goes Live in EPIC as Part of a First-Time Integration in Canada
For children diagnosed with complex heart conditions like hypertrophic cardiomyopathy (HCM), the diagnosis can be frightening for families and challenging for healthcare providers since the trajectory of the condition is often uncertain. As a leading cause of sudden...Why we must screen early in life for hypertrophic cardiomyopathy
New study aims to change screening guidelines
U of T health-care collaborations share $3.5 million in new federal funding
U of T health-care collaborations share $3.5 million in federal funding
Cardiac Connections: Dr. Jason Maynes
Researching cellular mechanisms of HF and treating young patients
Preventing tragedy in cardiomyopathy
A precision tool to stop sudden cardiac death in children
Engineering a child-friendly heart valve
Finding new answers for those born with congenital heart defects
Precision medicine: the path to a cure
Where decoding the genes of children with HF will lead
Studying heart disease… in the 3rd trimester
What do dramatic blood flow changes inside expecting mothers mean for women with pre-existing heart conditions – and the unborn babies inside them?